Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nicholas Trakul, MD, PhD, Jeremy P

Published byHelge Bertelsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Nicholas Trakul, MD, PhD, Jeremy P"— Presentation transcript:

1 Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors 
Nicholas Trakul, MD, PhD, Jeremy P. Harris, BS, MPhil, Quynh-Thu Le, MD, Wendy Y. Hara, MD, Peter G. Maxim, PhD, Billy W. Loo, MD, PhD, Maximilian Diehn, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 9, Pages (September 2012) DOI: /JTO.0b013e31825f22ce Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Outcomes of SABR reirradiation after local recurrence. A, Kaplan-Meier estimates of LC for reirradiated tumors (black line), compared with the control group of tumors that had not received prior irradiation (gray line). B, Kaplan-Meier estimates of progression-free survival of reirradiated (black line) and control (gray line) patients. C, Kaplan-Meier estimates of overall survival (OS) of reirradiated (black line) and control (gray line) patients. D, Kaplan-Meier estimates of LC for reirradiated tumors with time to retreatment (TTR) ⩽ 16 months (black line) or TTR > 16 months (gray line). The median TTR in this cohort was 16 months. LC, local control. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31825f22ce) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Example of SABR reirradiation for a patient with local recurrence after an initial course of SABR. A, First treatment course of SABR for a right lower lobe non–small-cell lung cancer. Prescribed dose was 50 Gy in four fractions. B, Second course of SABR after biopsy confirmed local progression. Prescribed dose was 20 Gy in a single fraction. Volumes: orange ­shading = gross tumor volume, red shading = planning target volume. Isodose curves: magenta 50%, yellow 100%, and cyan 110% of prescription dose. C, Six-month follow-up positron emission tomography/computed tomography scan showing shrinkage, metabolic response, and mild local inflammation. SABR, stereotactic ablative radiotherapy. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31825f22ce) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Nicholas Trakul, MD, PhD, Jeremy P"

Similar presentations

Vertebral Fractures After Stereotactic Ablative Radiotherapy of Lung Tumors Todd A. Aguilera MD PhD 1, Nicholas Trakul MD PhD 2, David B. Shultz MD PhD.

Vertebral Fractures After Stereotactic Ablative Radiotherapy of Lung Tumors Todd A. Aguilera MD PhD 1, Nicholas Trakul MD PhD 2, David B. Shultz MD PhD.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Image–Guided Radiation Therapy for Non–small Cell Lung Cancer

Image–Guided Radiation Therapy for Non–small Cell Lung Cancer
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.

Feasibility and Potential Utility of Multicomponent Exhaled Breath Analysis for Predicting Development of Radiation Pneumonitis After Stereotactic Ablative.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.

Radiotherapy for Postoperative Thoracic Lymph Node Recurrence of Non–Small-Cell Lung Cancer Provides Better Outcomes If the Disease Is Asymptomatic and.
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

Similar presentations

Ads by Google